These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21744171)

  • 1. Immunogenicity of therapeutic proteins: the use of animal models.
    Brinks V; Jiskoot W; Schellekens H
    Pharm Res; 2011 Oct; 28(10):2379-85. PubMed ID: 21744171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical models used for immunogenicity prediction of therapeutic proteins.
    Brinks V; Weinbuch D; Baker M; Dean Y; Stas P; Kostense S; Rup B; Jiskoot W
    Pharm Res; 2013 Jul; 30(7):1719-28. PubMed ID: 23649852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products.
    Marszal E; Fowler E
    J Pharm Sci; 2012 Oct; 101(10):3555-9. PubMed ID: 22736535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics.
    Baker M; Carr F
    Curr Drug Saf; 2010 Oct; 5(4):308-13. PubMed ID: 20615174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for the preclinical and clinical characterization of immunogenicity.
    Koren E; Mytych D; Koscec M; Ferbas J; Gupta S; Moxness M; Swanson S
    Dev Biol (Basel); 2005; 122():195-200. PubMed ID: 16375262
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in predicting and manipulating the immunogenicity of biotherapeutics and vaccines.
    Flower DR
    BioDrugs; 2009; 23(4):231-40. PubMed ID: 19697965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations.
    Johnson R; Jiskoot W
    J Pharm Sci; 2012 Oct; 101(10):3586-92. PubMed ID: 22736238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.
    Smith A; Manoli H; Jaw S; Frutoz K; Epstein AL; Khawli LA; Theil FP
    J Immunol Res; 2016; 2016():2342187. PubMed ID: 27579329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxicity and immunogenicity of biopharmaceuticals: design concepts and safety assessment.
    Bhogal N
    Curr Drug Saf; 2010 Oct; 5(4):293-307. PubMed ID: 20615176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying MAPPs Assays to Assess Drug Immunogenicity.
    Karle AC
    Front Immunol; 2020; 11():698. PubMed ID: 32373128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to prediction of immune responses to therapeutic proteins during preclinical development.
    Perry LC; Jones TD; Baker MP
    Drugs R D; 2008; 9(6):385-96. PubMed ID: 18989990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of immunogenicity for therapeutic proteins: state of the art.
    De Groot AS; Moise L
    Curr Opin Drug Discov Devel; 2007 May; 10(3):332-40. PubMed ID: 17554860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans.
    Bugelski PJ; Treacy G
    Curr Opin Mol Ther; 2004 Feb; 6(1):10-6. PubMed ID: 15011776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective.
    Bee JS; Goletz TJ; Ragheb JA
    J Pharm Sci; 2012 Oct; 101(10):3580-5. PubMed ID: 22736570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taking immunogenicity assessment of therapeutic proteins to the next level.
    Büttel IC; Chamberlain P; Chowers Y; Ehmann F; Greinacher A; Jefferis R; Kramer D; Kropshofer H; Lloyd P; Lubiniecki A; Krause R; Mire-Sluis A; Platts-Mills T; Ragheb JA; Reipert BM; Schellekens H; Seitz R; Stas P; Subramanyam M; Thorpe R; Trouvin JH; Weise M; Windisch J; Schneider CK
    Biologicals; 2011 Mar; 39(2):100-9. PubMed ID: 21353596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro models for immunogenicity prediction of therapeutic proteins.
    Groell F; Jordan O; Borchard G
    Eur J Pharm Biopharm; 2018 Sep; 130():128-142. PubMed ID: 29894817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the tiered immunogenicity testing of biologics the adequate approach in preclinical development?
    Sauerborn M
    Bioanalysis; 2013 Apr; 5(7):743-6. PubMed ID: 23534419
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins.
    Sauna ZE; Lagassé D; Pedras-Vasconcelos J; Golding B; Rosenberg AS
    Trends Biotechnol; 2018 Oct; 36(10):1068-1084. PubMed ID: 29908714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins.
    Rosenberg AS; Verthelyi D; Cherney BW
    J Pharm Sci; 2012 Oct; 101(10):3560-7. PubMed ID: 22736548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters.
    Barbosa MD
    Drug Discov Today; 2011 Apr; 16(7-8):345-53. PubMed ID: 21300174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.